Synthetic Biologics Inc (NYSE:SYN) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 9,620,972 shares, an increase of 3.2% from the October 14th total of 9,323,722 shares. Based on an average daily volume of 302,946 shares, the days-to-cover ratio is presently 31.8 days. Currently, 12.9% of the company’s shares are sold short.

Synthetic Biologics (NYSE:SYN) opened at 0.89 on Wednesday. The stock’s market cap is $82.03 million. The firm has a 50 day moving average of $1.56 and a 200-day moving average of $1.77. Synthetic Biologics has a 52-week low of $0.85 and a 52-week high of $3.09.

Synthetic Biologics (NYSE:SYN) last issued its earnings results on Tuesday, November 1st. The company reported ($0.09) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.01. Equities analysts anticipate that Synthetic Biologics will post ($0.35) earnings per share for the current fiscal year.

A number of equities analysts recently commented on the stock. Zacks Investment Research upgraded shares of Synthetic Biologics from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research report on Tuesday, August 9th. FBR & Co restated a “buy” rating on shares of Synthetic Biologics in a research report on Friday, August 5th. BTIG Research began coverage on shares of Synthetic Biologics in a research report on Thursday, August 25th. They issued a “buy” rating and a $5.00 price objective on the stock. Finally, Griffin Securities set a $5.80 price objective on shares of Synthetic Biologics and gave the company a “buy” rating in a research report on Wednesday, August 31st.

Several institutional investors have recently modified their holdings of the company. California State Teachers Retirement System raised its position in shares of Synthetic Biologics by 0.9% in the third quarter. California State Teachers Retirement System now owns 160,201 shares of the company’s stock worth $276,000 after buying an additional 1,500 shares in the last quarter. Northern Trust Corp raised its position in shares of Synthetic Biologics by 1.3% in the third quarter. Northern Trust Corp now owns 835,051 shares of the company’s stock worth $1,437,000 after buying an additional 10,670 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Synthetic Biologics by 0.6% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,790,891 shares of the company’s stock worth $3,080,000 after buying an additional 11,349 shares in the last quarter. Rhumbline Advisers raised its position in shares of Synthetic Biologics by 16.9% in the third quarter. Rhumbline Advisers now owns 81,644 shares of the company’s stock worth $140,000 after buying an additional 11,800 shares in the last quarter. Finally, Morgan Stanley raised its position in shares of Synthetic Biologics by 13.8% in the third quarter. Morgan Stanley now owns 124,808 shares of the company’s stock worth $215,000 after buying an additional 15,106 shares in the last quarter.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

5 Day Chart for NYSE:SYN

Receive News & Stock Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related stocks with our FREE daily email newsletter.